

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 91204

Title: Hemorrhagic Cystitis in Gastric Cancer after Nab-paclitaxel: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04105454

Position: Editorial Board

Academic degree: MD

Professional title: Professor

Reviewer's Country/Territory: Egypt

Author's Country/Territory: China

Manuscript submission date: 2023-12-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-27 13:36

Reviewer performed review: 2023-12-27 14:19

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

It is well written case report and authors proved that hemorrhagic cystitis us due to chemotherapy and manage the case well

PEER-REVIEW REPORT

Name of journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 91204

Title: Hemorrhagic Cystitis in Gastric Cancer after Nab-paclitaxel: A case report

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06250974

Position: Peer Reviewer

Academic degree: MD

Professional title: Assistant Professor, Doctor, Instructor, Staff Physician, Teacher

Reviewer's Country/Territory: Thailand

Author's Country/Territory: China

Manuscript submission date: 2023-12-24

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-12-24 15:50

Reviewer performed review: 2023-12-30 00:17

Review time: 5 Days and 8 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This manuscript is reporting an interesting case of a patient with gastric cancer who was given Nab-paclitaxel and developed hemorrhagic cystitis. Detailed comments about this study are as follows: -In Figure 3, some texts are underlined with red as follows: "SMZ, Flavoxate," and "mesna." Please improve them. -In Figure 3, please change the dates "2023-06-20," "2023-09-23," and "2023-11-21" to the day after the given nab-PTX. -Was there a limitation to the conduction of the study other than the limitation of availability of drugs for advanced gastric cancer that led the patient to continue to receive five cycles of nab-PTX combined with S-1 chemotherapy? -As the authors stated, "Since 1992, PTX has been approved by the FPA for the treatment of ovarian cancer and various forms, such as docetaxel, albumin-bound PTX, and liposome PTX, have been approved for cancer treatment." Who is the FPA? Please state it more clearly. -Is the nab-paclitaxel related to hemorrhagic cystitis as dose-related? -Owing to demonstrate the causality of adverse events of the drug (Nab-paclitaxel), were there some methods used to support that hemorrhagic cystitis caused by Nab-paclitaxel, such as Naranjo's algorithm (adverse drug reaction probability scale)? -According to the pharmacokinetics of Nab-paclitaxel,



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
<https://www.wjgnet.com>

there is a small amount of renal excretion (4% unchanged, less than 1% changed), then reaches the urinary bladder (reference: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021660s037lbl.pdf).

What is the evidence to support that hemorrhagic cystitis is caused by Nab-paclitaxel? Also, what is the possibility of the mechanism of the hemorrhagic cystitis caused by Nab-paclitaxel? Why the other part of the urinary tract is not susceptible to hemorrhagic injury?